KEYTRUDA QLEX

all catalysts(0)

nothing on the calendar yet

News(10)

• Opinion: One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he was
  “The United States invented this platform and is the only country walking away from it,” Jeff Coller writes of mRNA vaccines.
  stat · 12d ago
• Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
  Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
  biopharma_dive · 13d ago
• 5 NextGen winners who went public this year (and which ones are hiring)
  BioSpace NextGen honorees made up one-third of the U.S. biotechs that have publicly debuted in 2026. Most are looking for biopharma professionals to join their teams.
  biospace · 13d ago
• Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
  The anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside seco…
  biospace · 14d ago
• Medicare drug price rule may target under-the-skin Keytruda and Opdivo
  For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.
  biopharma_dive · 2mo ago
• Pembrolizumab Plus BCG Elicits 92% CR Rate in BCG-Naive Very High-Risk T1 NMIBC
  Pembrolizumab plus BCG achieved a 92% 6-month complete response rate in very high-risk T1 bladder cancer with no progression to muscle-invasive disease.
  onclive · 3mo ago
• Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian Cancer
  The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.
  onclive · 3mo ago
• Biomarker-Driven Treatment Decisions and Managing Progression After Frontline Immunotherapy
  Upfront biomarker testing reshapes endometrial cancer care, guiding targeted and immune therapy—and exposing gaps in second-line options.
  onclive · 3mo ago
• Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Cancer
  Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.
  onclive · 3mo ago
• Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond
  Dr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.
  onclive · 3mo ago